Avoro Capital Advisors Adds $14M in Ocular Therapeutix, Inc. ($OCUL)
Avoro Capital Advisors raised its investment in OCUL by 14.3%, according to its recent 13F filing.
Key Points
- Avoro Capital Advisors boosted its OCUL holdings by 1,537,223 shares, totaling 12,315,000 shares valued at $110.1 million.
- OCUL shares traded at $8.94, with a 52-week range between $6.50 and $10.20, and a market cap not provided.
- Analysts like RBC Capital and HC Wainwright & Co. reiterated buy ratings, with price targets up to $30.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Avoro Capital Advisors has increased its investment in OCUL, as revealed in its latest 13F filing with the SEC. The firm added 1,537,223 shares, bringing its total to 12,315,000 shares. This marks a 14.3% increase in its holdings, now valued at approximately $110.1 million as of the reporting period.
What Changed in Avoro Capital Advisors' OCUL Position
Avoro Capital Advisors raised its stake in OCUL from 10,777,777 shares to 12,315,000 shares, an addition of 1,537,223 shares. This move represents a 14.3% increase in their position, reflecting a strong interest in the company as of the latest reporting period.
Other Institutional Activity in OCUL
FMR LLC increased its OCUL holdings by 868,159 shares, ending with 32,653,764 shares worth about $276.6 million. DEEP TRACK CAPITAL, LP made a significant addition of 11,615,868 shares, bringing its total to 19,686,282 shares valued at $166.7 million. BLACKROCK, INC. also grew its stake by 530,537 shares, totaling 16,132,931 shares valued at approximately $136.6 million. Meanwhile, SUMMER ROAD LLC added 771,270 shares, reaching a total of 11,879,825 shares worth about $100.6 million.
Ocular Therapeutix, Inc. Stock Down 13.7%
Shares of OCUL traded around $8.94. The stock experienced a 52-week low of $6.50 and a high of $10.20. The company's financial ratios, including market cap, P/E ratio, and beta, were not provided in the available data.
$OCUL stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Ocular Therapeutix, Inc.
On June 10, 2026, several insiders bought shares of OCUL. Adrienne Graves acquired 44,000 shares, while Jason Shand Robins, the Chief Financial Officer, purchased 14,024 shares. Seung Suh Hong and Richard Lindstrom, MD, also bought 14,000 shares each. These transactions did not involve any planned sales under Rule 10b5-1.
Analysts Set New Price Targets
RBC Capital reiterated its buy rating for OCUL on May 6, 2026, with a price target of $30. HC Wainwright & Co. reaffirmed its buy rating with a $21 target on April 13, 2026. Clear Street and Needham maintained buy ratings with targets of $28 and $18, respectively, earlier in the year. The consensus among analysts is a strong buy, with an average target price reflecting optimism about the company's future prospects.
About OCUL
OCUL operates in the healthcare sector, focusing on developing and commercializing innovative eye care solutions. The company is dedicated to addressing unmet medical needs in ophthalmology, leveraging its expertise to improve patient outcomes. With a commitment to research and development, OCUL aims to bring new therapies to market that enhance vision and quality of life for patients around the world.
Bottom Line
Avoro Capital Advisors' decision to increase its stake in OCUL suggests confidence in the company's potential. While 13F filings are historical, they offer insights into the strategic moves of major investors. OCUL's stock performance and insider buying activity indicate interest in its future prospects, bolstered by positive analyst ratings and price targets.
Get Ocular Therapeutix, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OCUL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.